Harpoon Therapeutics Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Harpoon Therapeutics stock.
View analyst ratings for Harpoon Therapeutics or view top-rated stocks.

Wall Street analysts have given Harpoon Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Harpoon Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Harpoon Therapeutics.

Harpoon Therapeutics, Inc. (NASDAQ:HARP) released its quarterly earnings results on Thursday, May, 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.05. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 68.36% and a negative net margin of 428.95%.
View Harpoon Therapeutics' earnings history.

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HARP shares have increased by 14.9% and is now trading at $15.02.
View which stocks have been most impacted by COVID-19.

9 analysts have issued 1-year target prices for Harpoon Therapeutics' shares. Their forecasts range from $16.00 to $40.00. On average, they expect Harpoon Therapeutics' share price to reach $31.00 in the next twelve months. This suggests a possible upside of 106.4% from the stock's current price.
View analysts' price targets for Harpoon Therapeutics or view top-rated stocks among Wall Street analysts.

4 employees have rated Harpoon Therapeutics CEO Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among Harpoon Therapeutics' employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Harpoon Therapeutics include Immunocore (IMCR), Alector (ALEC), Replimune Group (REPL), C4 Therapeutics (CCCC), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX), Cortexyme (CRTX), ImmunityBio (IBRX), Krystal Biotech (KRYS), Translate Bio (TBIO), Valneva (VALN), BioAtla (BCAB), Ocugen (OCGN), AlloVir (ALVR) and Atara Biotherapeutics (ATRA).
View all of HARP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

(HARP) raised $76 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Harpoon Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include MPM Asset Management LLC (9.96%), Orbimed Advisors LLC (7.03%), BlackRock Inc. (5.15%), Franklin Resources Inc. (3.30%), Sectoral Asset Management Inc (1.94%) and Nantahala Capital Management LLC (1.39%). Company insiders that own Harpoon Therapeutics stock include Ansbert Gadicke, Bioscience Plc Arix, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche, Impact Fund (Cayman) Oncology, Mark Chin, Natalie Sacks and Patrick Baeuerle.
View institutional ownership trends for Harpoon Therapeutics.

HARP stock was sold by a variety of institutional investors in the last quarter, including MPM Asset Management LLC, GSA Capital Partners LLP, Royal Bank of Canada, Morgan Stanley, Russell Investments Group Ltd., Alliancebernstein L.P., Nuveen Asset Management LLC, and Chartwell Investment Partners LLC. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Ansbert Gadicke, Bioventures 2014 LP Mpm, Holger Wesche, and Impact Fund (Cayman) Oncology.
View insider buying and selling activity for Harpoon Therapeutics or view top insider-selling stocks.

HARP stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Sectoral Asset Management Inc, Nantahala Capital Management LLC, Orbimed Advisors LLC, UBS Asset Management Americas Inc., Laurion Capital Management LP, BlackRock Inc., and Logos Global Management LP.
View insider buying and selling activity for Harpoon Therapeutics or or view top insider-buying stocks.

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HARP stock can currently be purchased for approximately $15.02.

Harpoon Therapeutics has a market capitalization of $488.51 million and generates $17.44 million in revenue each year. The company earns $-49,910,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis.

Harpoon Therapeutics employs 84 workers across the globe.

The official website for Harpoon Therapeutics is www.harpoontx.com.

Harpoon Therapeutics is headquartered at 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]